Be the first person to write a business review for LEO Pharma A/S

LEO Pharma- UK lays claim to being king of the dermatology drug jungle in the UK. LEO Pharma UK company, which is the British arm of Denmark's LEO Pharma, handles the sales and marketing LEO's dermatological and critical care pharmaceutical products in the UK. LEO Pharma UK also has a growing medical department which conducts clinical studies on behalf of the group. The parent company focuses on topical prescription medications for psoriasis and other dermatological conditions. The group's lead critical care products include anticoagulant heparin (derived from porcine mucosa) and vitamin D.

Servier is an independent, French pharmaceutical company which manufactures and sells drugs to combat cardiovascular diseases, such as coronary artery disease, hypertension, and stroke. Cardiovascular drugs account for about two-thirds of the company's annual revenues. It also produces medicines to treat diabetes, venous disease, and cancer. Annually, more than 700 million boxes of drugs are produced by Servier. Its pharmaceutics can be found in 140 countries; 80% of its sales are generated internationally.

Light Sciences Oncology, Inc. company is in the business of developing its proprietary Light Infusion Therapy (Litx). Litx is a novel treatment for solid tumors, in which a flexible light-emitting diode (LED) is inserted into a tumor, followed by an injection of Aptocine (talaporfin sodium), a light-activated drug. Once the LED activates Aptocine, molecular oxygen is converted into singlet oxygen, killing tissue within the LED's scope and shutting down the blood supply to the area. The treatment is designed for use on cancers including liver and prostate cancers and glioma (brain tumors).

Lonza Group stays busy making active ingredients. Spun off by Switzerland's former industrial giant Alusuisse Lonza Group (Algroup), Lonza Group is focused mostly on research and production for pharmaceutical and chemical firms. It is a contract manufacturer of the advanced intermediates and active ingredients used in drugs. Lonza also is active in biotechnology: It uses microbial fermentation and biotransformation to produce fine chemical intermediates and is involved in mammalian cell culture research. It also produces organic fine chemicals and performance chemicals (biocides and oleochemicals).

Luitpold Pharmaceuticals earns its gold from the businesses of drugs and medical devices. Luitpold markets and manufactures injectable products used to treat an array of ailments including kidney disease. Luitpold also manufactures materials used in dental bone grafting and bone regeneration and treatments for equine and canine joint diseases. The company, which targets its products primarily to hospitals and clinics in US and Canadian markets, operates through four divisions: American Regent, Luitpold Animal Health, Osteohealth, and Contract Manufacturing. Originally a German company named after a Bavarian prince, Luitpold is a subsidiary of one of Japan's largest pharmaceutical companies, Daiichi Sankyo.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.